Treatment of Disfiguring Cutaneous Lesions in Neurofibromatosis-1 with Everolimus: A Phase II, Open-Label, Single-Arm Trial

BACKGROUND: Cutaneous neurofibromas cause disfigurement and discomfort in individuals with neurofibromatosis type 1 (NF-1). METHODS: The primary objective of this phase II, open-label, single-arm trial was to assess whether orally administered everolimus reduced the surface volume of cutaneous neuro...

Descripción completa

Detalles Bibliográficos
Autores principales: Slopis, John M., Arevalo, Octavio, Bell, Cynthia S., Hebert, Adelaide A., Northrup, Hope, Riascos, Roy F., Samuels, Joshua A., Smith, Keri C., Tate, Patti, Koenig, Mary Kay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6277319/
https://www.ncbi.nlm.nih.gov/pubmed/30284154
http://dx.doi.org/10.1007/s40268-018-0248-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6277319/
https://www.ncbi.nlm.nih.gov/pubmed/30284154
http://dx.doi.org/10.1007/s40268-018-0248-6

Ejemplares similares